Ischemic heart disease can lead to myocardial infarction (MI), a major cause of morbidity and mortality worldwide. After MI scar forms in the affected region, the heart dilates, and cardiac function is depressed and can lead to heart failure. Current therapies do not reverse or reduce the death of tissue caused by MI. Cell therapy could be a new strategy to treat post MI remodeling, but to date has been largely ineffective. We have recently identified a novel stem cell that resides deep within the bone stroma, which we term Cortical Bone Stem Cells (CBSCs). We have shown, in a mouse MI model, that CBSCs reduce scar size and enhance cardiac function after MI. These beneficial effects appear to be mediated by paracrine mechanisms that we have shown can be cardioprotective, angiogenic, and immune modulatory. The proposed research is the next step in determining if these cells might be useful to treat patients who have suffered an MI.
The Aims of this research are to determine the best CBSC dose, route and time of delivery to induce more effective cardiac repair in a swine MI model. We will also determine if CBSCs improve post MI remodeling by cardioprotective, angiogenic, cardiogenic and/or immune modulatory effects. Our proposed study should provide novel insights into how to use cell therapy to improve cardiac structure and function after MI.
Cardiovascular disease is a major health problem in US leading to death of over a million people every year. Stem cell treatment has emerged as a possible therapy for heart failure patients. However, studies performed to date report that the beneficial effects of cell therapy are limited by poor retention and survival of the donated cells. We have identified a novel stem cell population, cortical bone derived stem cells (CBSCs) and have shown that they can reduce the scar size after myocardial infarction and thus augment heart function in mice. The current study will investigate the reparative capacity of CBSCs in a large pre clinical animal model in which we can use delivery techniques that would be suitable for human applications. We will test different doses and routes of delivery, and sex based effects of CBSCs in a clinically relevant animal model. The study should point the way for translation to treatments for heart failure.
